Well-Beans Program for Caregiver Stress in Tuberous Sclerosis
(TANDem-2 Trial)
What You Need to Know Before You Apply
What is the purpose of this trial?
This trial aims to determine if a new, short online program, the Well-Beans for Caregivers Program, can improve the well-being of caregivers for individuals with tuberous sclerosis complex (TSC). Researchers seek to assess the program's ease of online delivery, its perceived helpfulness by caregivers, and its impact on their lives. The trial seeks adult caregivers currently caring for someone with TSC. Participants will engage with the program and provide feedback on their experience. As an unphased trial, this study offers caregivers the chance to contribute to research that could enhance support for others in similar situations.
Do I have to stop taking my current medications for this trial?
The trial information does not specify whether you need to stop taking your current medications. It seems to focus on a behavioral program, so it's unlikely that medication changes are required.
What prior data suggests that the "Well-Beans for Caregivers" program is safe for caregivers?
Research has shown that the "Well-Beans for Caregivers" program is based on the World Health Organization's Caregiver Skills Training module. This program has been tested and helps caregivers manage stress and improve well-being. Early results suggest that most participants report a positive experience.
The program offers emotional support and practical skills, which are generally safe. No harmful side effects have been reported. As a behavioral program, it does not involve medication or physical treatments, which typically enhances its safety.
Overall, previous studies and its nature as a non-medical intervention indicate that the program is safe.12345Why are researchers excited about this trial?
Researchers are excited about the Well-Beans for Caregivers Program because it specifically addresses the stress experienced by caregivers of individuals with Tuberous Sclerosis, a need that is often overlooked by standard medical treatments. Unlike traditional approaches that focus on the patient, this program prioritizes the well-being of the caregiver through a structured, supportive framework. It aims to improve caregiver mental health and resilience, which can lead to better care for the patient. This novel focus on caregiver support rather than direct medical intervention is what makes the Well-Beans program stand out.
What evidence suggests that the "Well-Beans for Caregivers" program might be effective for caregiver stress in tuberous sclerosis?
Research has shown that the Well-Beans for Caregivers Program, which participants in this trial will experience, might improve caregivers' well-being and mental health. An earlier study found the program practical, well-received, and possibly helpful when used with a small group of caregivers. This short program focuses on boosting caregivers' emotional health, potentially reducing stress for those caring for individuals with tuberous sclerosis complex (TSC). While these results are encouraging, further research is needed to determine its effectiveness for larger groups.23678
Who Is on the Research Team?
Anna Jansen, MD, PhD
Principal Investigator
Vrije Universiteit Brussel
Petrus J de Vries, MD PhD
Principal Investigator
University of Cape Town
Are You a Good Fit for This Trial?
This trial is for adult caregivers of individuals with Tuberous Sclerosis Complex (TSC), regardless of the age of the person they care for. It aims to support their well-being.Inclusion Criteria
Timeline for a Trial Participant
Screening
Participants are screened for eligibility to participate in the trial
Intervention
Participants undergo the 'Well-Beans for Caregivers' program, consisting of three weekly sessions delivered online
Follow-up
Participants are monitored for changes in psychological flexibility, depression, anxiety, general wellbeing, and resilience
What Are the Treatments Tested in This Trial?
Interventions
- Well-Beans for Caregivers Program
Find a Clinic Near You
Who Is Running the Clinical Trial?
Vrije Universiteit Brussel
Lead Sponsor
University of Cape Town
Collaborator
United States Department of Defense
Collaborator